Published in final edited form as:

Bioorg Med Chem Lett. 2010 January 1; 20(1): 280–282. doi:10.1016/j.bmcl.2009.10.114.

A Single Step Purification for Autolytic Zinc Proteinases

Erin M. Wilfong, Ursala Locklear, and Eric J. Toone

Department of Chemistry, Duke University, LSRC B120, Durham NC 27708

Abstract

We describe a novel single-step method for the purification of stromelysin-1 catalytic domain (SCD) via immobilized metal affinity chromatography under denaturing conditions that inhibit proteolytic activity followed by on-column refolding and spontaneous autolysis of the fusion peptide to yield pure, active stromelysin-1 catalytic domain. The methodology provides a general approach for the rapid purification of large quantities of zinc proteinases.

The metal-dependent proteases encompass several large enzyme families, including the metzincin superfamily to which the matrix metalloproteinases (MMPs) belong. Disregulation of MMP expression and function is implicated in numerous pathophysiological processes,^{1–6} and a number of potent inhibitors of MMP activity have been developed and evaluated as clinical candidates.⁷ The matrix metalloproteinases also serve as important model systems for the study of structure-activity relationships in enzymatic catalysis, due to their highly variable substrate specificities despite a high degree of sequence homology. Despite their physiological and biophysical importance, the study of the MMP proteins is hindered by protein availability. Protein misfolding, the formation of insoluble occlusion bodies and autolysis all contribute to low and inconsistent isolated protein yields. Here, we report a robust, facile approach to MMP isolation and purification that overcomes these significant limitations.

MMPs are expressed physiologically as preproteins consisting of three domains – an N-terminal propeptide domain of roughly 80 residues, a large catalytic domain, and a C-terminal hemopoexin-like domain. The N-terminal prodomain contains a critical “cysteine switch” responsible for chelation of the catalytic zinc in the zymogen form.⁸ *In vitro*, MMPs are typically activated by the organomercurial aminophenyl mercuric acetate, although the mechanism by which this activation occurs remains obscure.^{8–10} Stable constructs lacking the N-terminal prodomain and thus requiring no activation have been expressed.¹¹ The next approximately 180 amino acids encode the catalytic domain, containing structural calcium and zinc ions, as well as the catalytic zinc.¹² Although the C-terminal hemopoexin-like domain is present in all MMPs except MMP-7 the domain is rarely included in recombinant MMP constructs since is proteolytically cleaved after MMP activation.^{13–17}

In the course of our studies on substrate specificity, we required a robust, reproducible expression and purification protocol for MMP sufficient to provide 100 mg quantities of pure protein. Although several purification protocols have been reported,^{11, 13–16} most are limited by the requirement for specialized equipment (ultracentrifuges and/or FPLC), cost,

©2000 Elsevier Science Ltd. All rights reserved.

Correspondence to: Eric J. Toone.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

and/or scale. Solid-phase IMAC procedures have been described for His₆-tagged variants of proMMP-7¹⁷ and proMMP-13,^{18, 19} but no reports of immobilized metal affinity chromatography (IMAC) purification of a catalytic domain exist. Obviation of organomercurial activation would be of clear value, especially for purification on the scale proposed here. Furthermore, the majority of protein isolated from IMAC proprotein purification is inactive due to misfolding, necessitating a second inhibitor- or substrate mimetic affinity purification to isolate active enzyme.¹⁸

To overcome limitations in the expression and purification of this important class of proteins we have developed a novel purification strategy that relies on metal affinity purification of inactive, partially denatured MMP, followed by refolding to yield active protein. The approach is reliable, highly reproducible and scalable.

A vector plasmid encoding amino acid residues 95–268 was constructed, representing the stromelysin catalytic domain and the final five residues of the prodomain to preserve the autolytic cleavage site. A plasmid containing stromelysin-1 c-DNA was a generous gift from Dr. L. Jack Windsor. The PCR primers 5'-TGC GGATCCCCTGATGTTGGTCAC TTC-3' and 5'-ATT CTCGAGCTATCAGGGATCCGG GGGAGGTCC-3' were used to amplify the desired sequence; a stop codon was introduced with the reverse primer. The amplified sequence was digested with BamHI and XhoI and ligated with T4 ligase into the pET28 vector (Novagen, Darmstadt Germany), introducing an N-terminal His₆-fusion peptide. The sequence was confirmed by DNA sequencing, and the construct was transformed into BL-21 (DE3) Gold cells (Stratagene, La Jolla CA) for expression.

A culture of transformed *E. coli* was grown at 37°C in terrific broth (TB) media supplemented with 30 mg L⁻¹ of kanamycin to OD_{600nm} 0.6–0.8; protein expression was induced with 1mM isopropyl-β-D-1-thiogalactopyranoside (IPTG) at 37°C for 6–8 hours. During expression, a 23 kDa protein appeared within 2 hours, corresponding to the mass expected for the soluble catalytic domain (SCD) plus vector-derived fusion peptide. Under these conditions, the protein expressed exclusively as inclusion bodies. Following cell harvesting and lysis, the insoluble debris was resuspended in a bind buffer of 6M urea, 250mM NaCl, and 20mM TrisHCl, pH 7.9 (20 mL per liter of growth) supplemented with 2% SDS (w/v) and shaken overnight at 37°C to solubilize the inclusion bodies.

The solution containing protein solubilized from inclusion bodies (360 mg in 17.6 mL) was diluted fourfold with bind buffer to yield a final sodium dodecyl sulfate (SDS) concentration of 0.5% w/v. A 15 mL bed volume of His-bind Resin (Novagen) was charged with 75 mL of 50 mM CoCl₂. Co(II) was preferable to Ni(II) due to its increased specificity for his₆-fusions.^{20, 21} The resin was equilibrated with 45 mL bind buffer and then loaded with protein solution. The solubilized recombinant protein bound efficiently to the resin; no recombinant protein was detected in the flow-through. It is noteworthy that the Novagen resin seems to be uniquely suited for this procedure: attempts to reproduce the protocol using other iminodiacetic acid resins were unsuccessful (data not shown). The column was washed with six bed volumes of bind buffer, 10 bed volumes of wash I (6M urea, 250mM NaCl, 5mM imidazole, 20mM TrisHCl, pH 7.9), and 10 bed volumes of wash II (6M urea, 500mM NaCl, 20mM imidazole, 20mM TrisHCl, pH 7.9).

The protein was refolded on the resin using a two-step refolding similar to that described for proMMP-13.¹⁸ The resin was washed with five bed volumes of refolding buffer (2.3M urea, 200mM NaCl, 10mM CaCl₂, 10μM ZnCl₂, 50mM TrisHCl, pH 7.78). The resin was allowed to stand for an additional twenty minutes before application of five bed volumes of elution buffer (200mM NaCl, 10mM CaCl₂, 1μM ZnCl₂, 50mM TrisHCl, pH 7.9). The eluate was collected in 10 mL aliquots; aliquots containing protein and absent visible Co(II)

were combined to yield a solution containing 10–15 mg L⁻¹ of active recombinant SCD lacking the fusion peptide; this material also reacted positively with anti-stromelysin-1 antibody. (Figure 1) The protein was dialyzed once against a 50X volume of elution buffer to remove residual urea and three times against calorimetry buffer (50mM TrisHCl, pH 7.5, 10mM CaCl₂). A circular dichroism spectrum was consistent with previous reports (data not shown). Table 1 summarizes the purification procedure.

The activity of the recovered SCD was verified by isothermal titration calorimetry (ITC) using previously described inhibitors; binding data are summarized in Table 2.^{14, 22, 23} The observation that ITC titrations uniformly yielded binding stoichiometries ranging from 0.9 to 1.08 confirmed that all recovered protein was active (data not shown).

The solid phase refolding procedure described above evolved from initial attempts at traditional solution phase refolding. MMPs require both Ca(II) and Zn(II) ions for proper refolding. In a solution phase procedure, the his₆-fusion peptide readily chelated these ions, resulting in large protein aggregates. Chelation of the his₆-fusion peptide to the IMAC resin renders it unavailable for cation binding, preventing aggregation.

A second limitation of solution phase refolding is contamination by soluble but misfolded protein that must be removed in a subsequent purification steps.^{11, 25, 26} Although contamination by inactive protein is acceptable for high-throughput screens, inactive contamination is a significant problem for applications requiring highly pure protein such as ITC and crystallography. These applications therefore require the previous IMAC procedures to be coupled with a successive affinity purification step.¹⁸ Contaminating inactive protein is completely avoided in our novel procedure. Our use of on-column refolding provides an *in situ* positive control for activity: only functional enzyme capable of autolysis and cleavage of the His₆-tag is recovered. In the absence of proper refolding, misfolded protein remains tethered to the immobilized matrix. A schematic of this process is shown in Figure 2.

Our procedure represents an operationally simple, general, and scalable approach to zinc metalloproteinase purification. The use of IMAC facilitates large scale purification, while *in situ* refolding ensures recovery of completely active protein. Although the process was validated here with a zinc proteinase, the protocol should be applicable to other metal-dependent proteolytic enzymes.

Acknowledgments

The authors thank Drs. Salvatore Pizzo, Mario Gonzalez-Gronow, Quintin Quinones and Andrea Luteran Yackenovitch for many helpful discussion and technical assistance. The authors are also grateful to Dr. Daphne Du for the synthesis of inhibitors.

References

1. Chang C, Werb Z. Trends Cell Biol. 2001; 11:S37. [PubMed: 11684441]
2. Churg A, Zay K, Shay S, Xie C, Shapiro SD, Hendricks R, Wright JL. Am. J. Respir. Cell Mol. Biol. 2002; 27:368. [PubMed: 12204900]
3. Coussens LM, Werb Z. Chem. and Biol. 1996; 3:895. [PubMed: 8939708]
4. Molet S, Belleguic C, Lena H, Germain N, Bertrand CP, Shapiro SD, Planquois JM, Delaval P, Lagente V. Inflamm. Res. 2005; 54:31. [PubMed: 15723202]
5. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Nat. Med. 1996; 2:461. [PubMed: 8597958]
6. Van den Steen PE, Opdenakker G, Wormald MR, Dwek RA, Rudd PM. Biochim. Biophys. Acta. 2001; 1528:61. [PubMed: 11687291]

7. Whittaker M, Floyd CD, Brown P, Gearing AJH. *Chem. Rev.* 1999; 99:2735. [PubMed: 11749499]
8. Wart HEV, Birkedal-Hansen H. *Proc. Natl. Acad. Sci. U.S.A.* . 1990; 87:5578. [PubMed: 2164689]
9. Chen LC, Noelken ME, Nagase H. *Biochemistry.* 1993; 32:10289. [PubMed: 8399171]
10. Springman EB, Angleton EL, Birkedalhansen H, Vanwart HE. *Proc. Natl. Acad. Sci. U.S.A.* . 1990; 87:364. [PubMed: 2153297]
11. Ye QZ, Johnson LL, Hupe DJ, Baragi V. *Biochemistry.* 1992; 31:11231. [PubMed: 1445862]
12. Pikul S, McDow Dunham KL, Almstead NG, De B, Natchus MG, Anastasio MV, McPhail SJ, Snider CE, Taiwo YO, Rydel T, Dunaway CM, Gu F, Mieling GE. *J. Med. Chem.* 1998; 41:3568. [PubMed: 9733482]
13. Suzuki K, Enghild JJ, Morodomi T, Salvesen G, Nagase H. *Biochemistry.* 1990; 29:5783. [PubMed: 2383557]
14. Bertini I, Calderone V, Fragai M, Luchinat C, Mangani S, Terni B. *J. Mol. Biol.* 2004; 336:707. [PubMed: 15095982]
15. Fu JY, Lyga A, Shi H, Blue ML, Dixon B, Chen D. *Protein Expr. Purif.* 2001; 21:268. [PubMed: 11237688]
16. Murphy G, Segain JP, Oshea M, Cockett M, Ioannou C, Lefebvre O, Chambon P, Basset P. *J. Biol. Chem.* 1993; 268:15435. [PubMed: 8340372]
17. Windsor LJ, Steele DL, LeBlanc SB, Taylor KB. *Biochim. Biophys. Acta.* 1997; 1334:261. [PubMed: 9101722]
18. Marcy AI, Eiberger LL, Harrison R, Chan HK, Hutchinson NI, Hagmann WK, Cameron PM, Boulton DA, Hermes JD. *Biochemistry.* 1991; 30:6476. [PubMed: 1647201]
19. Olejniczak ET, Hajduk PJ, Marcotte PA, Nettesheim DG, Meadows RP, Edalji R, Holzman TF, Fesik SW. *J. Am. Chem. Soc.* 1997; 119:5828.
20. Soler D, Nomizu T, Brown WE, Shibata Y, Auld DS. *J. Protein Chem.* 1995; 14:511. [PubMed: 8561847]
21. Steele DL, El-Kabbani O, Dunten P, Windsor LJ, Kammlott RU, Crowther RL, Michoud C, Engler JA, Birktoft JJ. *Protein Eng.* 2000; 13:397. [PubMed: 10877850]
22. Itoh M, Masuda K, Ito Y, Akizawa T, Yoshioka M, Imai K, Okada Y, Sato H, Seiki M. *J. Biochem.* 1996; 119:667. [PubMed: 8743567]
23. Hardern IM, Knauper V, Ernill RJ, Taylor IWF, Cooper KL, Abbott WM. *Protein Expr. Purif.* 2000; 19:246. [PubMed: 10873537]
24. Pathak N, Hu SI, Koehn JA. *Protein Expr. Purif.* 1998; 14:283. [PubMed: 9790892]
25. Hedman ES, Zhao YJ, Sulkowski E, Porath J. *Proc. Natl. Acad. Sci. U.S.A.* 1989; 86:181.
26. Yip TT, Nakagawa Y, Porath J. *Anal. Biochem.* 1989; 183:159. [PubMed: 2619040]
27. Hajduk PJ, Sheppard G, Nettesheim DG, Olejniczak ET, Shuker SB, Meadows RP, Steinman DH, Carrera GM, Marcotte PA, Severin J, Walter K, Smith H, Gubbins E, Simmer R, Holzman TF, Morgan DW, Davidsen SK, Summers JB, Fesik SW. *J. Am. Chem. Soc.* 1997; 119:5818.
28. MacPherson LJ, Bayburt EK, Capparelli MP, Carroll BJ, Goldstein R, Justice MR, Zhu L, Hu S, Melton RA, Fryer L, Goldberg RL, Doughty JR, Spirito S, Blancuzzi V, Wilson D, O'Byrne EM, Ganu V, Parker DT. *J. Med. Chem.* 1997; 40:2525. [PubMed: 9258358]
29. Edelhoch H. *Biochemistry.* 1967; 6:1948. [PubMed: 6049437]
30. Becker JW, Marcy AI, Rokosz LL, Axel MG, Burbaum JJ, Fitzgerald PMD, Cameron PM, Esser CK, Hagmann WK, Hermes JD, Springer JP. *Protein Sci.* 1995; 4:1966. [PubMed: 8535233]

Figure 1.

Autolysis of his₆-fusion peptide with refolding. Lane 1, standards; lane 2, purified SCD eluted prior to refolding; lane 3, eluate after solid phase refolding.

Figure 2.

Schematic of solid phase refolding. The protein is purified while denatured (left). Upon refolding, only some of the protein is refolded properly (middle) and the rest is either misfolded or trapped as a protein folding intermediate. Properly refolded enzyme regains activity, autolyzes the fusion peptide tethering it to the resin and elutes from the column.

Table 1

Protein Purification

Fraction	Volume (mL)	Concentration (mg/mL)	Total protein (mg)	Enrichment Factor
Crude Lysate	15.2	48.4	736.9	n.a.
Insoluble Crude Fraction	17.6	20.4	359	2.08
Purified Protein	36.0	0.38	13.7	53.8

Table 2

Binding Data

Compound	IC ₅₀ or K _D (Lit)	K _D (Exp)
43nM ²⁸	7 nM.
113nM ²⁸	43 nM
100 nM ¹⁹	110 nM
11 μM ¹⁹	17 μM

^aValues are means of three or more experiments

^bProtein concentrations were determined by the method of Edelhoch²⁴ using $\epsilon_{280} = 27630$ units.